# “Should I stay or should I go”—a kinase delays escape of Candida glabrata from macrophages

**Authors:** Theresa Lange, Colin Clairet, Luisa Fischer, Raghav Vij, Johannes Sonnberger, Julia Mantke, Nadja Jablonowski, Eric Seemann, Britta Qualmann, Christophe d’Enfert, Lydia Kasper, Bernhard Hube, Sascha Brunke

PMC · DOI: 10.1128/mbio.03885-25 · 2026-02-20

## TL;DR

Candida glabrata delays its escape from immune cells using a kinase, which helps it survive and resist antifungal drugs.

## Contribution

The study identifies Ksp1 kinase as a regulator of C. glabrata's delayed escape from macrophages and its role in antifungal resistance.

## Key findings

- C. glabrata delays escape from macrophages, which is controlled by fungal protein kinases like Ksp1.
- Deletion of Ksp1 increases mitophagy and respiration-deficient petite cells, enhancing antifungal resistance.
- Prolonged intracellular survival and petite formation are key to C. glabrata's immune evasion and recurrence.

## Abstract

Candida glabrata is an opportunistic fungal pathogen that causes both superficial and systemic infections in humans, accounting for 15%–25% of invasive candidiasis cases. Macrophages play a crucial role in antifungal immunity by internalizing C. glabrata; however, the fungus has evolved strategies to survive and even proliferate within phagosomes. It has been suggested that C. glabrata may utilize its life within macrophages to evade immune detection and disseminate throughout the body. We observed that, compared to fungi like C. albicans, C. glabrata only slowly escapes from macrophages, with host cells bursting after 2–3 days. This delay is fungal-driven rather than host-induced and is not solely due to replication in the yeast form per se. We identified protein kinases involved in exit timing, especially the Ksp1 kinase, the deletion of which accelerates macrophage cell lysis. Its loss increases mitophagy and the formation of petites, a respiration-deficient phenotype associated with resistance toward antifungals and, more importantly, to phagocytic killing. Moreover, deletion of KSP1 enhances resistance to multiple antifungals, suggesting that this kinase may be at the core of a broader cross-adaptive survival strategy by C. glabrata. Collectively, our findings indicate that C. glabrata may actively prolong its intramacrophagal phase, which could contribute to immune evasion, antifungal resistance, and potential recurrence of infection. Moreover, these results reinforce the notion of a critical role of petite formation in persistent and recurrent infections. They also show the need to adapt clinical diagnostics and therapy to detect and manage these respiration-deficient variants.

Candida glabrata is a major cause of invasive candidiasis and is difficult to treat due to its intrinsic resistance to antifungal drugs and its ability to survive inside host immune cells. How this pathogen regulates its intracellular lifestyle and exit from macrophages remains poorly understood. We show that C. glabrata actively modulates its interaction with macrophages through the protein kinase Ksp1, which regulates mitochondrial dysfunction and the formation of respiration-deficient cells. These variants display enhanced resistance to two antifungal drugs and killing by phagocytes. Our findings suggest that prolonging the intramacrophage phase and generating stress-resistant variants are key components of C. glabrata’s survival strategy. Recognizing these processes has important implications for clinical diagnostics and the management of persistent and recurrent fungal infections.

## Linked entities

- **Genes:** KSP1 (putative serine/threonine protein kinase KSP1) [NCBI Gene 856482]
- **Proteins:** KSP1 (putative serine/threonine protein kinase KSP1)
- **Diseases:** invasive candidiasis (MONDO:0044067)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ATG11 (autophagy protein ATG11) [NCBI Gene 856162] {aka CVT3, CVT9}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, ATG8 (ubiquitin-like protein ATG8) [NCBI Gene 852200] {aka APG8, AUT7, CVT5}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, ATG32 (mitophagy protein ATG32) [NCBI Gene 854660] {aka ECM37}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, KSP1 (putative serine/threonine protein kinase KSP1) [NCBI Gene 856482], ATG17 (protein kinase regulatory subunit ATG17) [NCBI Gene 851142] {aka APG17}
- **Diseases:** mitochondrial deficiency (MESH:D028361), inflammatory (MESH:D007249), candidemia (MESH:D058387), hypoxic (MESH:D002534), hypoxia (MESH:D000860), necrotic epithelial damage (MESH:D009375), invasive candidiasis (MESH:D058365), mitochondria-deficient (MESH:C564971), hMDMs (MESH:D055501), Cytotoxicity (MESH:D064420), respiration-deficient (MESH:D012120), C. glabrata infections (MESH:D007239), candidiasis (MESH:D002177), invasive (MESH:D009361), Petites (MESH:D004832), fungal (MESH:D009181)
- **Chemicals:** oxygen (MESH:D010100), osmium tetroxide (MESH:D009993), aromatic amino acids (MESH:D024322), 2,3,5-triphenyltetrazolium chloride (MESH:C009591), PI (MESH:D010716), TE (MESH:D013691), carbon (MESH:D002244), azole (MESH:D001393), Triton X-100 (MESH:D017830), agar (MESH:D000362), EDTA (MESH:D004492), nitrogen (MESH:D009584), nourseothricin (MESH:D013309), water (MESH:D014867), phenol (MESH:D019800), ethanol (MESH:D000431), copper (MESH:D003300), SDS (MESH:D012967), isopropanol (MESH:D019840), isoamyl alcohol (MESH:C029683), PEG (MESH:C000595214), echinocandin (MESH:D054714), dithiothreitol (MESH:D004229), glycerol (MESH:D005990), AlexaFluor647 (MESH:C569686), DNTPack (-), Propidium iodide (MESH:D011419), TCA (MESH:D014238), uranyl acetate (MESH:C005460), MgSO4 (MESH:D008278), amino acid (MESH:D000596), ammonium sulfate (MESH:D000645), chloroform (MESH:D002725), CO2 (MESH:D002245), ATP (MESH:D000255), fluconazole (MESH:D015725), poly(A (MESH:D011061), caspofungin (MESH:D000077336), glucose (MESH:D005947), formaldehyde (MESH:D005557), DAPI (MESH:C007293), tryptophan (MESH:D014364), HS (MESH:D006859), KCl (MESH:D011189), glutaraldehyde (MESH:D005976)
- **Species:** Candida albicans (species) [taxon 5476], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Candidozyma auris (species) [taxon 498019], Mus musculus (house mouse, species) [taxon 10090], Nakaseomyces glabratus (species) [taxon 5478], Cryptococcus neoformans (Cryptococcus neoformans serotype A, species) [taxon 5207], Fungi (kingdom) [taxon 4751], Nakaseomyces glabratus CBS 138 (strain) [taxon 284593], Histoplasma capsulatum (species) [taxon 5037], Danio rerio (leopard danio, species) [taxon 7955], Candida [taxon 1535326], Homo sapiens (human, species) [taxon 9606], Mycobacterium tuberculosis (species) [taxon 1773], Staphylococcus aureus (species) [taxon 1280]
- **Mutations:** C in 300
- **Cell lines:** ATCC2001 — Homo sapiens (Human), Xeroderma pigmentosum, complementation group A, Induced pluripotent stem cell (CVCL_YR67), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), J774A.1 — Mus musculus (Mouse), Mouse reticulum cell sarcoma, Cancer cell line (CVCL_0358)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12977481/full.md

---
Source: https://tomesphere.com/paper/PMC12977481